论文部分内容阅读
目的：了解CCLG-ALL2008方案治疗儿童急性淋巴细胞白血病（ALL）复发患儿的临床特征。方法选取2008年4月至2013年6月间初诊为儿童ALL，并接受CCLG-ALL2008方案治疗的591例患儿，回顾性分析并随访观察其中80例复发患儿的临床特征。结果 CCLG-ALL2008方案治疗后标危组、中危组、高危组复发率分别为7.0%、10.7%、28.7%（P<0.05）。TEL/AML1阳性ALL患儿复发率为8.0%，其复发患儿5年预期总生存率（OS）为37.04%；MLL阳性与BCR/ABL阳性ALL患儿复发率分别为35.0%和24.2%，5年OS为0。复发者以超早期为主，占53%，超早期复发者5年OS为0；早期和晚期复发分别占34%和14%，其5年OS分别为11.44%和60.00%。复发部位以单纯骨髓复发为主（83%），单纯骨髓复发患儿5年OS为9.23%；骨髓伴有骨髓外复发患儿占11%，其5年OS为25.00%；单纯骨髓外复发患儿占6%，其5年OS为100%。T细胞型ALL患儿复发率为9.5%，其复发患儿5年OS为0；B细胞型ALL患儿复发率为14.3%，其复发患儿5年OS为15.52%。结论 CCLG-ALL2008方案治疗后高危组患儿复发率较高；MLL、BCR/ABL等基因阳性是高危复发因素。免疫分型与复发率无明显相关性。早期复发、单纯骨髓复发、T细胞型ALL复发及伴有BCR/ABL、MLL等基因异常者复发后生存率极低。“,”ObjectiveTo study the clinical features of children with relapsed acute lymphoblastic leukemia (ALL) treated with the CCLG-ALL2008 protocol.Methods The data of 591 children who were newly diagnosed with ALL and were treated with the CCLG-ALL 2008 protocol between April 2008 and June 2013 were collected, and the clinical features of 80 children with relapsed ALL were retrospectively analyzed.ResultsAfter treatment with the CCLG-ALL2008 protocol, the recurrence rate in the standard-risk, intermediate-risk and the high-risk groups were 7.0%, 10.7%and 28.7% respectively (P<0.05). The recurrence rate in patients with TEL/AML1-positive ALL was 8.0%, and the 5-year overall survival (OS) of the relapsed patients was 37.04%. The recurrence rates in patients with MLL-positive and BCR/ABL-positive ALL were 35.0% and 24.2% respectively, and none of the relapsed patients had long-term survival. The recurrence mainly occurred at the very early stage (53%), and none of patients with recurrence at the very early stage had long-term survival. The recurrence occurred at early stage and late stage accounted for 34% and 14% respectively, and the 5-year OS rates of patients with recurrence at early stage and late stage were 11.44% and 60.00% respectively. The sites of recurrence were mainly bone marrow alone (83%), and the 5-year OS of patients with recurrence at bone marrow alone was 9.23%. The recurrence in bone marrow and outside bone marrow accounted for 11%, and the 5-year OS of patients with recurrence in both bone marrow and outside bone marrow was 25.00%. The recurrence only outside bone marrow accounted for 6%, and the 5-year OS of patients with recurrence only outside bone marrow was 100%. The recurrence rate in patients with T-cell ALL was 9.5%, and none of the relapsed patients had long-term survival. The recurrence rate in patients with B-cell ALL was 14.3%, and the 5-year OS of the relapsed patients was 15.52%. ConclusionsAfter treatmentwith the CCLG-ALL2008 protocol, a relatively high recurrence rate is observed in children with high-risk ALL. Positive MLL and positive BCR/ABL are high-risk factors for recurrence. The recurrence rate is not signiifcantly correlated with immunophenotype. A very low survival rate is seen in children whose recurrence have the following features: at early stage, only in bone marrow, T-cell ALL, and abnormal BCR/ABL and MLL.